Medicine and Dentistry
Bladder Cancer
100%
Non Muscle Invasive Bladder Cancer
66%
Bacilli
66%
Muscle Invasive Bladder Cancer
43%
Recurrent Disease
42%
COVID-19
33%
Surveillance System
33%
Radiation Therapy
33%
Cell Line
33%
Immunotherapy
33%
Recurrence Free Survival
30%
Diseases
29%
Clinical Trial
28%
Cystoscopy
27%
Transitional Cell Carcinoma
26%
Neoplasm
25%
Regulon
22%
Drug Sensitivity
22%
Cystectomy
19%
Adverse Event
19%
Severe Acute Respiratory Syndrome Coronavirus 2
16%
Tumor Microenvironment
13%
Lactic Acid
13%
Urinary Tract
12%
Progression Free Survival
12%
Bladder
12%
Bladder Cancer Cell Line
11%
High-Content Screening
11%
Differential Display
11%
In Vitro
11%
Knock Out
11%
Functional Genomics
11%
Drug Screening
11%
Transcriptome
11%
Overall Survival
11%
Drug Response
11%
Integrin
11%
Urinalysis
10%
Feces
8%
SARS Coronavirus
8%
Virus Detection
8%
Virus Particle
8%
Coronavirinae
8%
Urological Care
8%
Lamina Propria
8%
Chemoradiotherapy
7%
Urine Cytology
7%
Immune Response
6%
T Cell Activation
6%
Host Cell
6%
Biochemistry, Genetics and Molecular Biology
Clinical Trial
66%
Mitogen-Activated Protein Kinase
33%
Urine Sampling
33%
Cell Cycle
33%
DNA Damage Response
33%
Gene Signature
33%
Regulon
33%
Turnaround Time
33%
Drug Sensitivity
33%
ITGAV
33%
Cancer Cell
16%
Drug Response
16%
Overall Survival
16%
Functional Genomics
16%
Transcriptome
16%
HRAS
16%
Drug Screening
16%
Differential Display
16%
Integrin
16%
Methylation
16%
Pharmacology, Toxicology and Pharmaceutical Science
Bladder Cancer
33%
Drug Discovery
33%
Muscle Invasive Bladder Cancer
33%
Non Muscle Invasive Bladder Cancer
33%
Bacilli
33%
Chemotherapy
33%
Clinical Trial
22%
High-Content Screening
22%
Adverse Event
19%
Recurrence Free Survival
14%
Overall Survival
11%
Integrin
11%
Transcriptome
11%
